PDE4 inhibitors have no effect on eotaxin expression in human primary bronchial epithelial cells

• Autorzy: Paplinska-Goryca M. , Chazan R. , Grubek-Jaworska H.
• Języki publikacji: EN

Abstrakty

EN

 The bronchial epithelium is a very important factor during the inflammatory response, it produces many key regulators involved in the pathophysiology of asthma and COPD. Local influx of eosinophils, basophils, Th2 lymphocytes and macrophages is the source of many cytotoxic proteins, cytokines and other mediators of inflammation. These cells are attracted by eotaxins (eotaxin-1/CCL11, eotaxin-2/CCL24, eotaxin-3/CCL26). Inhibitors of phosphodiesterase 4 (PDE4) are new anti-inflammatory drugs which cause cAMP accumulation in the cell and inhibit numerous stages of allergic inflammation. The aim of our study was to evaluate the influence of PDE4 inhibitors: rolipram and RO-20-1724 on the expression of eotaxins in human primary bronchial epithelial cells. Cells were preincubated with PDE4 inhibitors for 1 hour and then stimulated with IL-4 or IL-13 alone or in combination with TNF-α. After 48 hours, eotaxin protein level was measured by ELISA and mRNA level by real time PCR. These cells produce CCL24 and CCL26. PDE4 inhibitors increased CCL24 and CCL26 mRNA level irrespectively of the used stimulators. Rolipram and RO-20-1724 had no effect on eotaxin protein production in our experimental conditions. Thus PDE4 inhibitors have no effect on eotaxin protein expression in human primary bronchial epithelial cells. In vitro experiments should be performed using a primary cell model rather than immortalized lines.

Słowa kluczowe

EN

PDE4 inhibitor; eotaxin expression; eotaxin; primary bronchial epithelial cell; bronchial epithelium; inflammatory response; chronic obstructive pulmonary disease

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2012
• Tom: 59
• Numer: 3
• Opis fizyczny: p.371-375,fig.,ref.

Twórcy

autor

Paplinska-Goryca M.

• Department of Internal Medicine, Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland

autor

Chazan R.

autor

Grubek-Jaworska H.

Bibliografia

• Badewa AP, Hudson CE, Heiman AS (2002) Regulatory effects of eotaxin eotaxin-2 and eotaxin-3 on eosinophil degranulation and superoxide anion generation. Exp Biol Med (Maywood) 227: 645-651. 
• Berkman N, Ohnona S, Chung FK, Breuer R (2001) Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 24: 682-687. 
• Buenestado A, Grassin-Delyle S, Naline E, Faisy C, Israël-Biet D, Sage E, Bellamy JF, Tenor H, Devillier P (2011) Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol 165 1877-1890  
• Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685-694. 
• Chen G, Gharib TG, Huang CC, Taylor JMG, Misek DE, Kardia SLR, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM et al. (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1: 304-313. 
• Chu YT, Chang TT, Jong YJ, Kuo PL, Lee HM, Lee MS, Chang HW, Hung CH (2010) Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells. Pediatr Allergy Immunol 21: 345-352. 
• Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, Sharma P, Seth MK, Balachandran S, Gupta N et al (2009) Pharmacology of a novel orally active PDE4 inhibitor. Pharmacology 83: 275-286. 
• Dent G, Hadjicharalambous C, Yoshikawa T, Handy RL, Powell J, Anderson IK, Louis R, Davies DE, Djukanovic R (2004) Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am J Respir Crit Care Med 169: 1110-1117. 
• Eskandari N, Wickramasinghe T, Peachell PT (2004) Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils. Br J Pharmacol 142: 1265-1272. 
• Fujisawa T, Kato Y, Atsuta J, Terada A, Iguchi K, Kamiya H, Yamada H, Nakajima T, Miyamasu M, Hirai K (2000) Chemokine production by the BEAS-2B human bronchial epithelial cells: differential regulation of eotaxin IL-8 and RANTES by TH2- and TH1-derived cytokines. J Allergy Clin Immunol 105: 126-133. 
• Gauvreau GM, Boulet L-P, Schmid-Wirlitsch C, Côté J, Duong M, Killian KJ, Milot J, Deschesnes F, Strinich T, Watson RM et al. (2011) Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 12: 140. 
• Giembycz MA, Field SK (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 4: 147-158. 
• Greenbaum D, Colangelo C, Williams K, Gerstein M (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4: 117. 
• Griego SD, Weston CB, Adams JL, Tal-Singer R, Dillon SB (2000) Role of p38 mitogen-activated protein kinase in rhinovirus-induced cytokine production by bronchial epithelial cells. J Immunol 165: 5211-5220. 
• Gry M, Rimini R, Strömberg S, Asplund A, Pontén F, Uhlén M, Nilsson P (2009) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10: 365. 
• Heiman AS, Abonyo BO, Darling-Reed SF, Alexander MS (2005) Cytokine-stimulated human lung alveolar epithelial cells release eotaxin-2 (CCL24) and eotaxin-3 (CCL26). J Interferon Cytokine Res 25: 82-91. 
• Hervé R, Schmitz T, Evain-Brion D, Cabrol D, Leroy MJ, Méhats C (2008) The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells. J Immunol 181: 2196-2202. 
• Joubert P, Lajoie-Kadoch S, Labonté I, Gounni AS, Maghni K, Wellemans V, Chakir J, Laviolette M, Hamid Q, Lamkhioued B (2005) CCR3 expression and function in asthmatic airway smooth muscle cells. J Immunol 175: 2702-2708. 
• Kim J, Myers AC, Chen L, Pardoll DM, Truong-Tran QA, Lane AP, McDyer JF, Fortuno L, Schleimer RP (2005) Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol 33: 280-289. 
• Kobayashi I, Yamamoto S, Nishi N, Tsuji K, Imayoshi M, Inada S, Ichiamaru T, Hamasaki Y (2004) Regulatory mechanisms of Th2 cytokine-induced eotaxin-3 production in bronchial epithelial cells: possible role of interleukin 4 receptor and nuclear factor-kappaB. Ann Allergy Asthma Immunol 93: 390-397. 
• Komiya A, Nagase H, Yamada H, Sekiya T, Yamaguchi M, Sano Y, Hanai N, Furuya A, Ohta K, Matsushima K et al. (2003) Concerted expression of eotaxin-1 eotaxin-2 and eotaxin-3 in human bronchial epithelial cells. Cell Immunol 225: 91-100. 
• Li GW, Xie XS (2011) Central dogma at the single-molecule level in living cells. Nature 475: 308-315. 
• Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, Rothenberg ME, Drazen JM, Luster AD (1997) Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 99: 1767-1773. 
• Liu J, Muñoz NM, Meliton AY, Zhu X, Lambertino AT, Xu C, Myo S, Myou S, Boetticher E, Johnson M et al (2004) Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils. Pulm Pharmacol Ther 17: 73-79. 
• Matsukura S, Kokubu F, Kurokawa M, Kawaguchi M, Ieki K, Kuga H, Odaka M, Suzuki S, Watanabe S, Takeuchi H, Kasama T, Adachi M (2006) Synthetic double-stranded RNA induces multiple genes related to inflammation through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway epithelial cells. Clin Exp Allergy 36: 1049-1062. 
• Menzies-Gow A, Ying S, Sabroe I, Stubbs VL, Soler D, Williams TJ, Kay AB (2002) Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils basophils neutrophils and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 169: 2712-2718. 
• Murphy DM, Ward C, Forrest IA, Pritchard G, Jones D, Stovold R, Fisher AJ, Cawston TE, Lordan JL, Corris PA (2006) The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients. J Heart Lung Transplant 25: 1436-1440. 
• Nejman-Gryz P, Grubek-Jaworska H, Glapiński J, Hoser G, Chazan R (2006) Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. J Physiol Pharmacol 57 (Suppl 4): 229-239. 
• Oei E, Kalb T, Beuria P, Allez M, Nakazawa A, Azuma M, Timony M, Stuart Z, Chen H, Sperber K (2004) Accessory cell function of airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 287: L318-331. 
• Pang L, Knox AJ (2001) Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. Faseb J 15: 261-269. 
• Paplinska M, Chazan R, Grubek-Jaworska H (2011) Effect of phoshpodiesterase 4 (PDE4) inhibibtors on eotaxin expression in humen bronchial epithelial cells. J Physiol Pharmacol 62: 303-311. 
• Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163: 53-67. 
• Reddel RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, Su RT, Brash DE, Park JB, Rhim JS, Harris CC (1988) Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 48: 1904-1909. 
• Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ (2011) Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 12: 18. 
• Rokudai A, Terui Y, Kuniyoshi R, Mishima Y, Mishima Y, Aizu-Yokota E, Sonoda Y, Kasahara T, Hatake K (2006) Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast. Biol Pharm Bull 29: 1102-1109. 
• Sabatini F, Petecchia L, Boero S, Silvestri M, Klar J, Tenor H, Beume R, Hatzelmann A, Rossi GA (2010) A phosphodiesterase 4 inhibitor roflumilast N-oxide inhibits human lung fibroblast functions in vitro. Pulm Pharmacol Ther 23: 283-291. 
• Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R (2006) Identification and validation of differences in protein levels in normal premalignant and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res 66: 11194-11206. 
• Silva PM, Alves AC, Serra MF, Pires AL, Silva JP, Barreto EO, Cordeiro RS, Jose PJ, Teixeira MM, Lagente V, Martins MA (2001) Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br J Pharmacol 134: 283-294. 
• Stewart CE, Torr EE, Mohd Jamili NH, Bosquillon C, Sayers I (2012) Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J Allergy (Cairo) 2012: 943982. 
• Suzuki T, Yamaya M, Sekizawa K, Yamada N, Nakayama K, Ishizuka S, Kamanaka M, Morimoto T, Numazaki Y, Sasaki H (2000) Effects of dexamethasone on rhinovirus infection in cultured human tracheal epithelial cells. Am J Physiol Lung Cell Mol Physiol 278: L560-571. 
• Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ, Angell ADR, Solanke YE, Lucas FS, Wiseman J et al. (2011) GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro kinetic and in vivo characterization. J Pharmacol Exp Ther 337: 145-154. 
• Wuyts WA, Vanaudenaerde BM, Dupont LJ, Demedts MG, Verleden GM (2003) Modulation by cAMP of IL-1beta-induced eotaxin and MCP-1 expression and release in human airway smooth muscle cells. Eur Respir J 22: 220-226.